Biotechnology
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

$376.8M

Market Cap • 4/2/2025

2015

(10 years)

Founded

2018

(7 years ago)

IPO

NASDAQ

Listing Exchange

Flag of GB

London

Headquarters